Equivalence by Design for Advanced Dosage Forms and Drug Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Equivalence by Design for Advanced Dosage Forms and Drug Products
FDA has been encouraging drug sponsors to use a systematic approach such as quality-by-design principles for pharmaceutical development.


Pharmaceutical Technology
Volume 33, Issue 10, pp. 104-110

Challenges of advanced dosage forms and delivery systems

Advances in pharmaceutical science and technology have led to an increasing growth in pharmaceutical dosage forms, including the availability of various modified-release platforms (e.g., sustained-, delayed-, and pulsatile-release) and complex drug delivery systems (e.g., liposomes, drug-eluting stents, and nanotechnology-derived products). In view of the intricate features of these products, pharmaceutical scientists have encountered significant challenges, ranging from designing and manufacturing such products with high quality to demonstrating and evaluating therapeutic equivalence between generic and innovator drugs.

The following is a recent example relating to the establishment of bioequivalence of liposome drug products. Liposomes are microscopic vesicles comprising one or more bilayers of amphipathic lipid molecules that enclose one or more aqueous compartments. Drug distribution in liposomes depends on the lipophilicity of the incorporated drug. Doxil (doxorubicin HCl liposome injection, Ortho Biotech Products, Bridgewater, NJ) is an example in which doxorubicin, a hydrophilic drug, is encapsulated in the aqueous space of the liposomes. In contrast, amphotericin B is hydrophobic, thus it is intercalated within the lipid bilayers of AmBisome (amphotericin B, Gilead Sciences, Foster City, CA). With the lipophilic surface, AmBisome is easily taken up by the endogenous macrophages residing in the reticuloendothelial system (RES). As a result, AmBisome has a relatively short residence time in the blood. On the contrary, the stealth liposome structure of Doxil protects the liposomes from RES uptake and prolongs circulation time in the bloodstream. With its long residence time in the blood and its small particle size (~100 nm), Doxil possesses an increased permeability through the altered and often compromised vasculature of tumors.

Given the potential of phagocytosis and extravasation processes occurring in vivo, one of the regulatory questions that have arisen is whether blood-level measurement can be used to assess bioequivalence of liposome drug products (4, 5). To address this question, one must understand the disposition of the liposome product under examination. For most conventional liposomes that are prone to RES uptake, it is unlikely that blood levels can be used to determine bioequivalence. Liposomes that are designed to avoid RES uptake may be able to circulate in the bloodstream for a long period of time. However, these liposomes have a greater chance of extravasating through the leaky vascular wall into various tissues. At issue is whether one can demonstrate that the test and reference products have comparable "rate and extent to which the active ingredient or active moiety becomes available at the site of action," a regulatory mandate for establishing bioequivalence (2). It is conceivable that similar questions may be raised for other targeted delivery systems, advanced dosage forms, and combination products.

The trend in the evaluation of therapeutic equivalence

In retrospect, over the decades, the field of biopharmaceutics has evolved from empirical science that investigates the bioavailability and pharmacokinetics of various formulations to more sophisticated mechanism-based approaches that delineate the relationship between drug kinetics and various formulation or administration factors at the molecular level. Similarly, the evolution in science and technology has provided regulatory scientists with opportunities to enhance the equivalence assessment of certain products on a mechanistic basis from time to time. A prominent example is the regulatory application of the Biopharmaceutics Classification System (BCS) that uses biopharmaceutical attributes (i.e., aqueous solubility and intestinal permeability) for predicting bioavailability and bioequivalence (6). The waiver of in vivo bioequivalence studies for a BCS I drug (highly soluble and highly permeable) has been relied on the mechanistic rationing that intrinsic gastric emptying (rather than formulation) is the "rate-limiting" step for in vivo delivery and absorption of the drug if it is formulated in a rapidly dissolving product.

Another example is cholestyramine resins for which in vitro equilibrium binding and in vitro kinetic binding studies have been used to determine bioequivalence by FDA (7). In essence, both in vitro assays use the resin's mechanism of action (i.e., binding of bile acid salts) to assess the binding behavior of different formulations. Undoubtedly, the continued progress in science and technology will facilitate a greater characterization of pharmaceutical attributes as well as better understanding of in vivo drug delivery and absorption processes so that more mechanism-based approaches can be used to establish therapeutic equivalence between products. The following section provides theoretical considerations for bioequivalence assessment, which may shed some light on how we can move forward in this area.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here